Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT ID: NCT01809600
Last Updated: 2017-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2013-02-28
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
NCT01226849
LMBA02 Protocol for Patients With a Burkitt Lymphoma
NCT00180882
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT02867566
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
2. age \>20 yrs
3. received rituximab+chemotherapy as first-line treatment
4. with measurable or evaluable lesion
5. with complete set of clinical and laboratory data for the analysis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Burkitt's Lymphoma
should be diagnosed pathologically by WHO 2008 criteria
No intervention (observational study)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention (observational study)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. age \>20 yrs
3. received rituximab+chemotherapy as first-line treatment
4. with measurable or evaluable lesion
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gachon University Gil Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junshik Hong
Assistant Professor, Department of Internal Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suk Jin Kim, MD, PhD
Role: STUDY_DIRECTOR
Samsung Medical Center, Seoul, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gachon University Gil Medical Center
Incheon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CISL-1203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.